Influence of the Immune Checkpoint Inhibitors on the Hemostatic Potential of Blood Plasma
This study characterizes the potential impact of pembrolizumab, nivolumab, and ipilimumab on hemostasis. Nivolumab and ipilimumab are able to reduce aggregation and increase the procoagulant properties of platelets, which can cause side effects associated with hemostatic imbalance leading to thrombosis or bleeding. The observed ICI-specific effects may contribute to our understanding of the mechanisms by which ICI affects platelets and suggest how, in a clinical setting, to reduce coagulation disorders during ICI treatment in the future.
Authors
- Michael Erdmann (ORCID: https://orcid.org/0000-0001-7136-6489)
- Sarah Cunningham (ORCID: https://orcid.org/0000-0001-8692-1211)
- Julian Schlüter (ORCID: https://orcid.org/0000-0003-0583-7021)
- Alexandra Wandersee
- Holger Hackstein (ORCID: https://orcid.org/0000-0001-9722-8180)
- Irina Patalakh
Institutions
- Friedrich-Alexander-Universität Erlangen-Nürnberg (DE)
- Universitätsklinikum Erlangen (DE)
- Palladin Institute of Biochemistry (UA)
Publication Details
- Journal
- Transfusion Medicine and Hemotherapy
- Published
- 2024-08-21
- DOI
- https://doi.org/10.1159/000535926
- Citations
- 4
- Primary Topic
- Platelet Disorders and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 1.82
Funders
- Friedrich-Alexander-Universität Erlangen-Nürnberg
- Deutsche Forschungsgemeinschaft
- Volkswagen Foundation